Snowden Capital Advisors LLC Sells 4,162 Shares of Kenvue Inc. (NYSE:KVUE)

Snowden Capital Advisors LLC reduced its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 1.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 219,581 shares of the company’s stock after selling 4,162 shares during the period. Snowden Capital Advisors LLC’s holdings in Kenvue were worth $4,688,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Wedmont Private Capital increased its holdings in shares of Kenvue by 11.5% in the 4th quarter. Wedmont Private Capital now owns 13,044 shares of the company’s stock valued at $272,000 after acquiring an additional 1,344 shares during the period. Assenagon Asset Management S.A. lifted its position in Kenvue by 270.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 843,901 shares of the company’s stock worth $18,017,000 after acquiring an additional 616,292 shares during the period. Park Avenue Securities LLC lifted its holdings in shares of Kenvue by 860.2% in the 4th quarter. Park Avenue Securities LLC now owns 232,282 shares of the company’s stock valued at $4,959,000 after buying an additional 208,092 shares during the period. Empirical Asset Management LLC acquired a new position in shares of Kenvue in the 4th quarter valued at about $1,145,000. Finally, Avanza Fonder AB acquired a new position in Kenvue in the 4th quarter worth about $4,009,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on KVUE. Citigroup upped their target price on Kenvue from $22.00 to $24.50 and gave the stock a “neutral” rating in a research note on Friday, May 9th. Barclays raised their target price on Kenvue from $22.00 to $23.00 and gave the company an “equal weight” rating in a report on Monday, May 12th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. Canaccord Genuity Group raised their price objective on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Finally, Evercore ISI started coverage on shares of Kenvue in a report on Monday, March 24th. They issued an “in-line” rating and a $25.00 target price on the stock. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $25.33.

Kenvue Price Performance

Shares of NYSE KVUE opened at $24.15 on Friday. The firm has a market capitalization of $46.34 billion, a P/E ratio of 45.57, a PEG ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a one year low of $17.67 and a one year high of $25.17. The company’s fifty day moving average is $23.16 and its two-hundred day moving average is $22.59. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.23 by $0.01. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The business had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. During the same period in the previous year, the firm earned $0.28 EPS. The business’s revenue for the quarter was down 3.9% compared to the same quarter last year. Analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be given a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.40%. Kenvue’s dividend payout ratio is presently 149.09%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.